Novapharm Innovation TechnologyStart a conversation

Pharmaceutical strategy & execution advisory

India · UK · International

Where pharmaceutical ambition becomes executable strategy.

We advise pharmaceutical leaders on growth, portfolio, product development, technology transfer, market entry, commercial readiness, supply resilience, and digital operating models.

Explore our expertise Discuss a decision

The work begins with a decision

Questions that change the direction of the business.

Leading advisory firms organise around the client's hardest decisions—not around a catalogue of services. That is now the organising principle of NIT.

01

Which products and markets deserve capital now?

02

How should we enter without overbuilding the organisation?

03

Which partner can execute—not merely promise?

04

Where will development or transfer fail before it becomes visible?

05

How do we build resilience without creating waste?

06

What should data and AI actually change in the operating model?

Our expertise

Specialist pharma depth. Integrated business judgement.

We connect strategy, science, manufacturing, markets, partners, operations, and technology—because pharmaceutical decisions rarely fail in only one function.

View all expertise

01

Strategy & growth

Choose where to play—and what it will take to win.

We help leadership teams turn broad growth ambition into a focused set of choices across markets, categories, channels, capabilities, and investment priorities.

Questions we help answer

  • Which growth spaces are strategically attractive and operationally credible?
  • What should be built, acquired, licensed, partnered, or exited?
  • Which assumptions matter most to the investment case?

Typical outputs

  • Growth thesis and strategic choices
  • Opportunity prioritisation
  • Scenario and risk architecture
  • Execution roadmap and governance

An end-to-end decision horizon

From product thesis to market performance.

Our perspective follows the full chain of value. We identify where a decision made today creates an advantage—or a hidden constraint—several stages later.

01Opportunity
02Portfolio
03Development
04Transfer
05Access
06Launch
07Scale

Perspective

India intelligence.
International perspective.

We work at the intersection of Indian pharmaceutical capability and international market expectations.

That perspective is valuable where development, manufacturing, licensing, distribution, quality, commercial, and market-entry choices must work across different operating realities. We translate between them without reducing either side to a stereotype.

About NIT

Sectors

Built for the businesses shaping access to health.

Explore sectors
01

Pharmaceuticals & generics

Portfolio choices, development pathways, international market entry, product acquisition, commercial readiness, and resilient supply models for established and growth-stage pharmaceutical businesses.

02

Biotech & specialty pharma

Decision support for focused portfolios, external innovation, partner strategy, asset positioning, development planning, and commercial pathway design where capital and specialist capability must be tightly allocated.

03

Consumer health & nutraceuticals

Category, portfolio, evidence, formulation, channel, brand, distribution, and international market-entry strategy for science-led consumer health businesses.

04

Medical devices & diagnostics

Product-market fit, partner selection, market-entry model, evidence and regulatory dependency mapping, launch readiness, and commercial pathway planning.

05

Manufacturers & CDMOs

Growth strategy, capability positioning, target-market alignment, customer proposition, technology-transfer readiness, programme governance, and partnership development for manufacturing organisations.

06

Distributors & market-access organisations

Portfolio strategy, supplier architecture, channel model, differentiated proposition, account strategy, data visibility, and operating resilience for organisations connecting products to markets.

Current thinking

Ideas designed to improve the next decision.

View all insights

Market entry · 6 min read

Approval is not access

Read perspective

Portfolio & supply · 7 min read

Portfolio resilience begins before sourcing

Read perspective

Development & manufacturing · 8 min read

Technology transfer is a governance problem before it is a technical one

Read perspective

We do not sell certainty.

We make uncertainty decision-ready.

The purpose of advisory work is not to make a complicated situation sound simple. It is to make the choices, evidence, trade-offs, responsibilities, and path to action clear enough to move with conviction.

How we work